Results 141 to 150 of about 2,763,321 (346)

OP28 Health Technology Assessment: A Situation Analysis Of Zimbabwe [PDF]

, 2022
Blessing Dzingirai, Celia Moffat Joel Matyanga, Pinky Manyau, Maarten Jacubos Postma, Marinus van Hulst, Nyashadzaishe Mafirakureva   +5 more
openalex   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

The history of the International Journal of Technology Assessment in Health Care [PDF]

, 2009
Egon Jonsson, Stanley Reiser
openalex   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Health Technology Assessment Programme [PDF]

Journal of Medical Screening, 2008
openaire   +2 more sources

Implementation of health technology assessment at the stage of market access for pharmaceuticals in Ukraine

, 2020
O Piniazhko, L. Kovtun, O. Zaliska, Oleksandra Oleshchuk, M. Leleka, O. Topachevskyi   +5 more
openalex   +2 more sources

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Institutionalizing Health Technology Assessment in Brazil: Challenges Ahead [PDF]

, 2012
Ricardo Kuchenbecker, Carísi Anne Polanczyk   +1 more
openalex   +1 more source

Kihívások a népegészségügyi intervenciók közgazdasági értékelésében [PDF]

, 2009
The full version of the article can be viewed at the link below.Economists face challenges when trying to apply the standard methods of economic evaluation to the area of public health.
Marianna, HT
core  

Screening for lung cancer: A systematic review of overdiagnosis and its implications

Molecular Oncology, EarlyView.
Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz, Laura de la Torre‐Perez, David R Baldwin, Carlijn van der Aalst, Mangesh Thorat, David Ritchie, Andre L Carvalho, Carolina Espina, Ivan Solà, Carlos Canelo‐Aybar, Moira Magdalena Pissinis, Pablo Alonso‐Coello, Ana Carolina Pereira Nunes Pinto   +12 more
wiley   +1 more source